Effective lutetium/ytterbium separation for no-carrier added lutetium-177 production-Reference-Cited by-同舟云学术

Effective lutetium/ytterbium separation for no-carrier added lutetium-177 production

Published:2022-11-16 Issue:12 Volume:331 Page:5719-5727
ISSN:0236-5731
Container-title:Journal of Radioanalytical and Nuclear Chemistry
language:en
Short-container-title:J Radioanal Nucl Chem

Author:

Zhuo Liangang,Yang Yuchuan,Yue Haidong,Xiong Xiaoling,Wang Guanquan,Wang Hailin,Yang Lin,Lin Qingchuan,Chen Qiping,Tu Jun,Wei Hongyuan,Yang Xia,Kan Wentao^ORCID

Funder

Key R&D Project of Sichuan Science and Technology Program

Nuclear Energy Development Project of State Administration of Science, Technology and Industry for National Defense

The Central Guidance for Local Science and Technology Development Projects

Publisher

Springer Science and Business Media LLC

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,Spectroscopy,Pollution,Radiology, Nuclear Medicine and imaging,Nuclear Energy and Engineering,Analytical Chemistry

Link

https://link.springer.com/content/pdf/10.1007/s10967-022-08588-4.pdf

Reference21 articles.

1. Koppe MJ (2004) Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 45:1224–1232

2. Brouwers AH (2004) Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45:327–337

3. Beckford Vera DR (2012) Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl Med Biol 39:3–13

4. Kogos B (2021) Electron microscopy of antibody-conjugated, lutetium-177 lanthanide gold-coated nanoparticles: Proof of concept of targeted loci-A potential theranostic agent. AIP Adv 11:045035

5. Pirooznia N (2020) 177Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: biological evaluation and preclinical study. Bioorg Chem 102:104100

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Removal of 177Lu from radioactive wastewater using Montmorillonite clay;Applied Radiation and Isotopes;2024-09

2. Lutetium-177 radioisotope and therapeutic radiopharmaceuticals: Production, separation and purification, chelation labeling and clinical application;Chinese Science Bulletin;2024-04-12

3. Alpha-hydroxyisobutyric acid-assisted solid-liquid chromatography for the separation of lutetium-177 from neutron-irradiated natural ytterbium;Radiochimica Acta;2024-02-06

4. Whole process establishment of carrier-free 177Lu production: from small-scale production to pilot-scale production;Journal of Radioanalytical and Nuclear Chemistry;2023-11-10